Longeveron (LGVN) Q4 2024 earnings summary

Executive summary

• Advanced Lomecel-B clinical programs in HLHS, Alzheimer's, and frailty, with positive results in multiple trials and significant regulatory progress, including RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease designations.

• HLHS ELPIS II pivotal trial reached over 90% enrollment, with completion expected in Q2 2025 and BLA submission targeted for 2026.

• Alzheimer's program received RMAT and Fast Track designations, with positive Phase 2a data presented at AAIC 2024 and further FDA engagement planned.

• WHO approved "laromestrocel" as the non-proprietary name for Lomecel-B, supporting future commercialization.

• Cash and cash equivalents stood at $19.2 million as of December 31, 2024, with no debt.

Financial highlights

• 2024 revenue was $2.4 million, up 237% year-over-year, driven by contract manufacturing and Bahamas Registry Trial demand.

• Gross profit rose to $1.9 million in 2024, up 752% from $0.2 million in 2023.

• Operating expenses declined 13% year-over-year; G&A expenses fell 16% to $10.3 million, and R&D expenses dropped 10% to $8.1 million.

• Net loss decreased 25% to $16 million from $21.4 million in 2023.

• Cash and equivalents at year-end were $19.2 million, expected to fund operations into Q4 2025.

Outlook and guidance

• ELPIS II enrollment expected to complete in Q2 2025, with top-line results anticipated in summer 2026 and BLA submission for HLHS targeted for 2026, contingent on positive results.

• Plans to meet with FDA in Q1 2025 to review Alzheimer's strategy; further partnerships and non-dilutive funding sought.

• Operating and capital expenses projected to accelerate in 2025 due to BLA-enabling activities and CMC readiness.

• Current cash expected to fund operations into Q4 2025; additional financing will be sought.